192 related articles for article (PubMed ID: 8485565)
1. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
[TBL] [Abstract][Full Text] [Related]
2. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus.
Wallace DJ; Linker-Israeli M; Hyun S; Klinenberg JR; Stecher V
J Rheumatol; 1994 Feb; 21(2):375-6. PubMed ID: 8182661
[No Abstract] [Full Text] [Related]
3. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs.
Rahman P; Gladman DD; Urowitz MB; Yuen K; Hallett D; Bruce IN
J Rheumatol; 1999 Feb; 26(2):325-30. PubMed ID: 9972966
[TBL] [Abstract][Full Text] [Related]
4. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
López P; Gómez J; Mozo L; Gutiérrez C; Suárez A
Arthritis Res Ther; 2006; 8(2):R42. PubMed ID: 16507146
[TBL] [Abstract][Full Text] [Related]
5. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.
López P; Gómez J; Prado C; Gutiérrez C; Suárez A
J Rheumatol; 2008 Aug; 35(8):1559-66. PubMed ID: 18597405
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
8. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Parke A; West B
J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
[TBL] [Abstract][Full Text] [Related]
10. Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Parke AL
J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of antimalarials in systemic lupus erythematosus.
Esdaile JM
Lupus; 1993 Feb; 2 Suppl 1():S3-8. PubMed ID: 8485568
[TBL] [Abstract][Full Text] [Related]
12. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus.
Bruce IN
Rheumatology (Oxford); 2005 Dec; 44(12):1492-502. PubMed ID: 16234277
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
14. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
McLaurin EY; Holliday SL; Williams P; Brey RL
Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
[TBL] [Abstract][Full Text] [Related]
15. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial drugs, pregnancy and lactation.
Parke AL
Lupus; 1993 Feb; 2 Suppl 1():S21-3. PubMed ID: 8485567
[TBL] [Abstract][Full Text] [Related]
17. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
18. Antimalarial agents and lupus.
Wallace DJ
Rheum Dis Clin North Am; 1994 Feb; 20(1):243-63. PubMed ID: 8153401
[TBL] [Abstract][Full Text] [Related]
19. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of antimalarials in systemic lupus erythematosus.
Nayak V; Esdaile JM
Lupus; 1996 Jun; 5 Suppl 1():S23-7. PubMed ID: 8803906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
